Floatz logo

Tvp-1012

Apathy

University Hospital, Clermont-FerrandPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Apathy cohort.

Asset / SponsorPhaseRating
Methylphenidate
Sunnybrook Health Sciences Centre
Phase 4BBB
Rivastigmine
University Hospital, Lille
Phase 3B
Rotigotine
University Hospital, Grenoble
Phase 3B
FEOBV F-18
University Hospital, Bordeaux
Phase 3B
Modafinil
Brown University
Phase 3B

View all 13 →

Same molecule, other indications

Tvp-1012 is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
78 / 100
View asset →
sleep disorderDormant
BB
Indicative ·
69 / 100
View asset →
depressive disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →